Several other equities analysts also recently commented on the company. CIBC cut their price objective on Rocky Mountain Dealerships from C$10.50 to C$10.00 in a research report on Thursday, May 2nd. SunTrust Banks upped their price objective on Accenture to $180.00 and gave the company a hold rating in a research report on Friday, March 29th. They noted that the move was a valuation call. Zacks Investment Research raised DLH from a sell rating to a hold rating in a research report on Tuesday, July 9th. Oppenheimer cut their price objective on Littelfuse from $215.00 to $210.00 and set an outperform rating on the stock in a research report on Thursday, May 2nd. Finally, Royal Bank of Canada reaffirmed an outperform rating on shares of in a research report on Tuesday, June 25th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and seven have given a buy rating to the company’s stock. The stock presently has a consensus rating of Buy and an average price target of $22.17.
Shares of Athenex stock opened at $19.98 on Thursday. The firm has a fifty day simple moving average of $17.25. The company has a debt-to-equity ratio of 0.57, a quick ratio of 1.85 and a current ratio of 2.22. Athenex has a 52 week low of $9.38 and a 52 week high of $21.11.
In other news, major shareholder Perceptive Advisors Llc bought 100,000 shares of the stock in a transaction on Monday, May 6th. The stock was acquired at an average cost of $12.71 per share, for a total transaction of $1,271,000.00. The acquisition was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Jordan Kanfer bought 2,500 shares of the stock in a transaction on Thursday, June 6th. The stock was purchased at an average price of $15.01 per share, with a total value of $37,525.00. Following the completion of the acquisition, the director now directly owns 4,184 shares in the company, valued at approximately $62,801.84. The disclosure for this purchase can be found here. Insiders acquired a total of 318,210 shares of company stock valued at $5,111,581 over the last quarter. Company insiders own 18.80% of the company’s stock.
Hedge funds have recently modified their holdings of the business. First Trust Advisors LP purchased a new stake in Athenex during the 1st quarter worth about $1,054,000. DekaBank Deutsche Girozentrale lifted its holdings in Athenex by 21.8% during the 1st quarter. DekaBank Deutsche Girozentrale now owns 22,900 shares of the company’s stock worth $366,000 after buying an additional 4,100 shares during the last quarter. Emory University purchased a new stake in shares of Athenex in the 1st quarter valued at about $2,312,000. BNP Paribas Arbitrage SA lifted its holdings in shares of Athenex by 913,400.0% in the 1st quarter. BNP Paribas Arbitrage SA now owns 9,135 shares of the company’s stock valued at $112,000 after purchasing an additional 9,134 shares during the last quarter. Finally, Virginia Retirement Systems ET AL purchased a new stake in shares of Athenex in the 1st quarter valued at about $158,000. Institutional investors and hedge funds own 31.21% of the company’s stock.
Athenex Company Profile
Athenex, Inc, a biopharmaceutical company, engages in the discovery, development, and commercialization of various therapies for the treatment of cancer and related conditions in North America and Asia. It operates in three segments: Oncology Innovation Platform, Global Supply Chain Platform, and Commercial Platform.
Featured Story: Cash Flow
Receive News & Ratings for Athenex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Athenex and related companies with MarketBeat.com's FREE daily email newsletter.